Global Testosterone Undecylate (TU) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Testosterone Undecylate (TU) market size will reach US$ million by 2031.

Testosterone undecanoate is the ester prodrug of testosterone and has a midchain fatty acid at the 17Beta position.It is available as an intramuscular injection and as an oral capsule, and is indicated for treatment of testosterone deficiency.

United States market for Testosterone Undecylate (TU) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Testosterone Undecylate (TU) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Testosterone Undecylate (TU) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Testosterone Undecylate (TU) players cover Organon, Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Testosterone Undecylate (TU) Industry Forecast” looks at past sales and reviews total world Testosterone Undecylate (TU) sales in 2024, providing a comprehensive analysis by region and market sector of projected Testosterone Undecylate (TU) sales for 2025 through 2031. With Testosterone Undecylate (TU) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Testosterone Undecylate (TU) industry.

This Insight Report provides a comprehensive analysis of the global Testosterone Undecylate (TU) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Testosterone Undecylate (TU) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Testosterone Undecylate (TU) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Testosterone Undecylate (TU) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Testosterone Undecylate (TU).

This report presents a comprehensive overview, market shares, and growth opportunities of Testosterone Undecylate (TU) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Injection
Oral

Segmentation by Application:
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Organon
Bayer AG
Endo Pharmaceuticals
Merck Sharp & Dohme
Taro Pharmaceutical
Cipla
Clarus Therapeutics
Zhejiang Xianju Pharmaceutical
Zhejiang Medicine

Please note: The report will take approximately 2 business days to prepare and deliver. Show more